Literature DB >> 35049494

Practice-changing publications: Muscle-invasive bladder cancer.

Khatereh Aminoltejari1, Girish Kulkarni1, Ross Mason2.   

Abstract

Entities:  

Year:  2021        PMID： 35049494      PMCID： PMC8937600          DOI： 10.5489/cuaj.7733

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  13 in total

1.  Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.

Authors:  Francesco Del Giudice; Giovanni Barchetti; Ettore De Berardinis; Martina Pecoraro; Vincenzo Salvo; Giuseppe Simone; Alessandro Sciarra; Costantino Leonardo; Michele Gallucci; Carlo Catalano; James W F Catto; Valeria Panebianco
Journal:  Eur Urol       Date:  2019-11-05       Impact factor: 20.096

2.  Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Authors:  Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin
Journal:  N Engl J Med       Date:  2017-02-17       Impact factor: 91.245

3.  Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.

Authors:  Maria F Becerra; Vivek Venkatramani; Isildinha M Reis; Nachiketh Soodana-Prakash; Sanoj Punnen; Mark L Gonzalgo; Shyamal Raolji; Erik P Castle; Michael E Woods; Robert S Svatek; Alon Z Weizer; Badrinath R Konety; Mathew Tollefson; Tracey L Krupski; Norm D Smith; Ahmad Shabsigh; Daniel A Barocas; Marcus L Quek; Atreya Dash; Dipen J Parekh
Journal:  J Urol       Date:  2020-04-09       Impact factor: 7.450

4.  Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.

Authors:  Dipen J Parekh; Isildinha M Reis; Erik P Castle; Mark L Gonzalgo; Michael E Woods; Robert S Svatek; Alon Z Weizer; Badrinath R Konety; Mathew Tollefson; Tracey L Krupski; Norm D Smith; Ahmad Shabsigh; Daniel A Barocas; Marcus L Quek; Atreya Dash; Adam S Kibel; Lynn Shemanski; Raj S Pruthi; Jeffrey Scott Montgomery; Christopher J Weight; David S Sharp; Sam S Chang; Michael S Cookson; Gopal N Gupta; Alex Gorbonos; Edward M Uchio; Eila Skinner; Vivek Venkatramani; Nachiketh Soodana-Prakash; Kerri Kendrick; Joseph A Smith; Ian M Thompson
Journal:  Lancet       Date:  2018-06-23       Impact factor: 79.321

5.  Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.

Authors:  Guru Sonpavde; Bryan H Goldman; V O Speights; Seth P Lerner; David P Wood; Nicholas J Vogelzang; Donald L Trump; Ronald B Natale; H Barton Grossman; E David Crawford
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

6.  Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.

Authors:  Ahmad Shabsigh; Ruslan Korets; Kinjal C Vora; Christine M Brooks; Angel M Cronin; Caroline Savage; Ganesh Raj; Bernard H Bochner; Guido Dalbagni; Harry W Herr; S Machele Donat
Journal:  Eur Urol       Date:  2008-07-18       Impact factor: 20.096

7.  Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

Authors:  Andrea Necchi; Andrea Anichini; Daniele Raggi; Alberto Briganti; Simona Massa; Roberta Lucianò; Maurizio Colecchia; Patrizia Giannatempo; Roberta Mortarini; Marco Bianchi; Elena Farè; Francesco Monopoli; Renzo Colombo; Andrea Gallina; Andrea Salonia; Antonella Messina; Siraj M Ali; Russell Madison; Jeffrey S Ross; Jon H Chung; Roberto Salvioni; Luigi Mariani; Francesco Montorsi
Journal:  J Clin Oncol       Date:  2018-10-20       Impact factor: 44.544

8.  Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Authors:  Andrea Necchi; Daniele Raggi; Andrea Gallina; Russell Madison; Maurizio Colecchia; Roberta Lucianò; Rodolfo Montironi; Patrizia Giannatempo; Elena Farè; Filippo Pederzoli; Marco Bandini; Marco Bianchi; Renzo Colombo; Giorgio Gandaglia; Nicola Fossati; Laura Marandino; Umberto Capitanio; Federico Dehò; Siraj M Ali; Jon H Chung; Jeffrey S Ross; Andrea Salonia; Alberto Briganti; Francesco Montorsi
Journal:  Eur Urol       Date:  2019-11-08       Impact factor: 20.096

9.  Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.

Authors:  Robert A Huddart; Emma Hall; Rebecca Lewis; Nuria Porta; Malcolm Crundwell; Peter J Jenkins; Christine Rawlings; Jean Tremlett; Leila Campani; Carey Hendron; Syed A Hussain; Nicholas D James
Journal:  Eur Urol       Date:  2019-12-13       Impact factor: 20.096

10.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.

Authors:  Alison Birtle; Mark Johnson; John Chester; Robert Jones; David Dolling; Richard T Bryan; Christopher Harris; Andrew Winterbottom; Anthony Blacker; James W F Catto; Prabir Chakraborti; Jenny L Donovan; Paul Anthony Elliott; Ann French; Satinder Jagdev; Benjamin Jenkins; Francis Xavier Keeley; Roger Kockelbergh; Thomas Powles; John Wagstaff; Caroline Wilson; Rachel Todd; Rebecca Lewis; Emma Hall
Journal:  Lancet       Date:  2020-03-05       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.